RAI- REFRACTORY PAPILLARY THYROID CARCINOMA: ONE OF THE FIRST PATIENTS TO USE LENVATINIB IN THE COUNTRY, CASE REPORT
INTRODUCTION: Thyroid cancer represents the most common tumor in women, approximately 10 to 20% of differentiated thyroid carcinomas (DTC) develop metastases, failure in treatment with iodine occurs in 50% of cases. The advent of Tyrosine Kinase Inhibitors (TKIs) has undergone a radical change in the pattern of treatment for DTC. OBJECTIVES: To report a case of Rai- refractory metastatic DTC, whose patient is one of the first to use lenvatinib in the country. CONCLUSIONS: With treatment, a patient under surveillance for metastatic diseases and multiple treatment line, exhibited response rates consistent with literary data, decreasing biochemical markers and manageable toxicity.
RAI- REFRACTORY PAPILLARY THYROID CARCINOMA: ONE OF THE FIRST PATIENTS TO USE LENVATINIB IN THE COUNTRY, CASE REPORT
-
DOI: 10.22533/at.ed.1592172221037
-
Palavras-chave: Carcinoma. Thyroid. Toxicity.
-
Keywords: Carcinoma. Thyroid. Toxicity.
-
Abstract:
INTRODUCTION: Thyroid cancer represents the most common tumor in women, approximately 10 to 20% of differentiated thyroid carcinomas (DTC) develop metastases, failure in treatment with iodine occurs in 50% of cases. The advent of Tyrosine Kinase Inhibitors (TKIs) has undergone a radical change in the pattern of treatment for DTC. OBJECTIVES: To report a case of Rai- refractory metastatic DTC, whose patient is one of the first to use lenvatinib in the country. CONCLUSIONS: With treatment, a patient under surveillance for metastatic diseases and multiple treatment line, exhibited response rates consistent with literary data, decreasing biochemical markers and manageable toxicity.
-
Número de páginas: 6
- Julia Pastorello
- Marina Ractz Bueno
- Camila dos Santos do Amaral
- Cristiane Pagnussat Cechetti
- Emanuela Lando
